Treatment with crizotinib for LCNEC with EML4-ALK rearrangement proved to be inefficient according to two case reports [39,40], but one case with PLB1-ALK rearrangements responded crizotinib [41]. The gene discussed is ALK; the disease is large cell neuroendocrine carcinoma.